Heartflow Files S-1/A Amendment 2, Nears Public Offering
Ticker: HTFL · Form: S-1/A · Filed: Aug 6, 2025 · CIK: 1464521
| Field | Detail |
|---|---|
| Company | Heartflow, Inc. (HTFL) |
| Form Type | S-1/A |
| Filed Date | Aug 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, IPO, Medical Devices, Surgical Instruments, SEC Filing, Heartflow Inc., Public Offering
Related Tickers: HTFL
TL;DR
**Heartflow is gearing up for its IPO, signaling a new med-tech player hitting the market soon.**
AI Summary
Heartflow, Inc. filed an S-1/A on August 6, 2025, as Amendment No. 2 to its Form S-1 Registration Statement, indicating its intent to commence a proposed sale to the public as soon as practicable. The company, operating under SIC Code 3841 (Surgical & Medical Instruments & Apparatus), is headquartered at 331 E. Evelyn Avenue, Mountain View, California. Heartflow, Inc. was formerly known as Cardiovascular Simulation, Inc. until its name change on May 19, 2009. The filing does not provide specific revenue or net income figures, nor does it detail key business changes or strategic outlook, focusing instead on the procedural aspects of its registration for a public offering. Key risks are not explicitly detailed in this amendment, which primarily updates the registration statement. The company's primary business involves medical instruments and apparatus, suggesting its financial performance will be tied to the healthcare sector's demand for its products.
Why It Matters
This S-1/A filing signals Heartflow's imminent public offering, providing investors with a potential new opportunity in the medical technology sector. For employees, a successful IPO could lead to increased equity value and growth opportunities within the company. Customers could benefit from increased investment in product development and broader market reach for Heartflow's surgical and medical instruments. In the competitive landscape, Heartflow's entry into the public market will intensify competition among medical device manufacturers, potentially driving innovation and pricing pressures.
Risk Assessment
Risk Level: medium — The risk level is medium because while the S-1/A itself doesn't detail financial risks, an IPO for a company in the 'Surgical & Medical Instruments & Apparatus' sector (SIC Code 3841) inherently carries market and operational risks. The lack of specific financial data in this amendment means investors are still awaiting crucial information to assess the company's valuation and future prospects, making it a speculative investment until more details emerge.
Analyst Insight
Investors should closely monitor subsequent filings for Heartflow, Inc. to obtain critical financial performance data, valuation metrics, and detailed risk factors before making any investment decisions. Evaluate the company's competitive advantages and market position within the medical device industry.
Key Numbers
- 0001628280-25-038091 — Accession Number (Unique identifier for the S-1/A filing)
- 2025-08-06 — Filing Date (Date S-1/A was filed with the SEC)
- 333-288733 — Registration No. (SEC file number for the S-1 registration statement)
- 3841 — SIC Code (Standard Industrial Classification for Surgical & Medical Instruments & Apparatus)
- 650-241-1221 — Business Phone (Contact number for Heartflow, Inc.)
- 2009-05-19 — Date of Name Change (When Cardiovascular Simulation, Inc. became Heartflow, Inc.)
Key Players & Entities
- Heartflow, Inc. (company) — Registrant for S-1/A filing
- John C.M. Farquhar (person) — President and Chief Executive Officer of Heartflow, Inc.
- Shelly Heyduk (person) — Contact for Heartflow, Inc.
- Angela Ahmad (person) — Contact for Heartflow, Inc.
- Dave Peinsipp (person) — Contact for Cooley LLP
- Ryan Coombs (person) — Contact for Cooley LLP
- Kristin VanderPas (person) — Contact for O'Melveny & Myers LLP
- Denny Won (person) — Contact for O'Melveny & Myers LLP
- Charles S. Kim (person) — Contact for O'Melveny & Myers LLP
- U.S. Securities and Exchange Commission (regulator) — Recipient of S-1/A filing
FAQ
What is the purpose of Heartflow, Inc.'s S-1/A filing on August 6, 2025?
The S-1/A filing on August 6, 2025, is Amendment No. 2 to Heartflow, Inc.'s Form S-1 Registration Statement, indicating the company's intent to commence a proposed sale to the public as soon as practicable after the effective date of the Registration Statement.
Who is the President and CEO of Heartflow, Inc.?
John C.M. Farquhar is listed as the President and Chief Executive Officer of Heartflow, Inc. in the S-1/A filing.
What is Heartflow, Inc.'s primary business classification?
Heartflow, Inc. is classified under Standard Industrial Classification (SIC) Code 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
When did Heartflow, Inc. change its name from Cardiovascular Simulation, Inc.?
Heartflow, Inc. changed its name from Cardiovascular Simulation, Inc. on May 19, 2009, according to the S-1/A filing.
What is the business address for Heartflow, Inc.?
The business address for Heartflow, Inc. is 331 E. Evelyn Avenue, Mountain View, California 94041, with a business phone number of (650) 241-1221.
What is the SEC file number for Heartflow, Inc.'s S-1 registration statement?
The SEC file number for Heartflow, Inc.'s S-1 registration statement is 333-288733.
Does this S-1/A filing contain detailed financial information for Heartflow, Inc.?
This specific S-1/A filing, Amendment No. 2, primarily updates the registration statement and does not provide detailed financial information such as revenue, net income, or specific dollar amounts for performance metrics. Investors would need to consult other sections of the full S-1 filing for such data.
Who are the legal counsels listed for Heartflow, Inc. in this filing?
Cooley LLP, with contacts Dave Peinsipp and Ryan Coombs, and O'Melveny & Myers LLP, with contacts Kristin VanderPas, Denny Won, and Charles S. Kim, are listed as legal counsels in the S-1/A filing.
What does 'As soon as practicable after the effective date of this Registration Statement' mean for investors?
This phrase indicates that the proposed sale to the public, or IPO, will occur shortly after the SEC declares the registration statement effective. Investors should be prepared for the offering to launch without significant further delay once effectiveness is achieved.
Is Heartflow, Inc. considered an emerging growth company based on this filing?
The filing includes checkboxes for various filer statuses (large accelerated filer, accelerated filer, non-accelerated filer, smaller reporting company, or emerging growth company) but does not explicitly check any of them in the provided text. Therefore, based solely on this excerpt, it is not confirmed whether Heartflow, Inc. is an emerging growth company.
Industry Context
Heartflow, Inc. operates within the Surgical & Medical Instruments & Apparatus sector (SIC Code 3841). This industry is characterized by innovation, stringent regulatory oversight, and significant capital investment. Companies in this space often focus on developing advanced diagnostic and therapeutic devices to address unmet medical needs, particularly in areas like cardiovascular disease.
Regulatory Implications
As a medical device company, Heartflow, Inc. is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with quality standards, clinical trial requirements, and post-market surveillance are critical. Any delays or issues in regulatory approval processes can significantly impact market access and financial performance.
What Investors Should Do
- Monitor SEC filings for further amendments to the S-1/A.
- Research the company's specific medical technology and its market adoption.
Key Dates
- 2025-08-06: Filing of Amendment No. 2 to Form S-1 Registration Statement — Indicates the company is moving forward with its IPO plans and has updated its registration statement for public sale.
- 2009-05-19: Company Name Change — Marks the transition from Cardiovascular Simulation, Inc. to Heartflow, Inc., reflecting a potential shift or refinement in business focus.
Glossary
- S-1/A
- An amendment to a company's initial S-1 registration statement filed with the SEC, used to update information before an initial public offering (IPO). (This filing is an S-1/A, indicating Heartflow, Inc. is in the process of going public and has made revisions to its initial registration.)
- SIC Code 3841
- Standard Industrial Classification code for Surgical & Medical Instruments & Apparatus. (Classifies Heartflow, Inc. within the medical device industry, providing context for its market and competitive landscape.)
- Registration Statement
- A document required by the SEC for companies planning to offer securities to the public, containing detailed financial and business information. (The S-1/A is an update to this crucial document, essential for the IPO process.)
Year-Over-Year Comparison
This filing is Amendment No. 2 to the S-1 Registration Statement. As it is an update to the initial IPO filing and does not provide comparative financial data from a prior period, a direct comparison of key metrics like revenue growth or margin changes is not possible at this stage. The focus remains on procedural updates for the public offering rather than a year-over-year financial performance review.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on August 6, 2025 by John C.M. Farquhar regarding Heartflow, Inc. (HTFL).